INTRODUCTION
The treatment of acute lymphoblastic leukemia (ALL) in low-middle-income countries (LMICs) faces many obstacles. Delayed diagnosis, malnutrition, inadequate supportive therapy, abandonment of therapy, shortage of chemotherapeutic agents, suboptimal treatment adherence, and genetic polymorphic variants may contribute to a negative prognosis. [1] [2] [3] [4] [5] [6] [7] In the last 20 years, the Monza International School of Pediatric Hematology-Oncology and the International Outreach Program (IOP) of St. Jude Children's Research Hospital (St. Jude) have contributed to the growth of pediatric oncology in Central America, where pediatric hemato-oncology centers have joined together to form the Pediatric Hematology-Oncology Association of Central America (AHOPCA). 8, 9 In this context, two ALL protocols have been implemented: the AHOPCA-ALL 2008 study, which was recently published, 10 and the Guatemala LLAG-0707, a single-institution study conducted at the National Pediatric Oncology Unit (UNOP), which provides a relatively high level of comprehensive health care. Children with ALL have been treated there according to a slightly modified ALL Intercontinental Berlin-Frankfurt-Münster (IC-BFM) 2002 protocol 11 since July 2007, and the results of that experience are reported herein.
MATERIALS AND METHODS

Study Design and Participants
Context
Guatemala has a particularly diverse society (in terms of ethnic groups, languages, and culture) and geography; its infrastructure is poor, and access to health services is difficult. Founded in 2000 with private and public funds, UNOP features intensive care, inpatient, and outpatient unit, with adequate staff for the different medical areas. Psychosocial support is very well organized, so abandonment of therapy is rare despite the widespread poverty in the region. 3, 12 Patients All children and adolescents with newly diagnosed ALL ages 1 to 17 years were eligible to participate in the LLAG-0707 study after informed consent was provided. Patients who had received previous treatment or who died before starting treatment were excluded. Patients who previously received treatment with steroids were included if the total dose did not exceed the equivalent of 2 mg/kg daily for 1 week. The diagnosis of ALL was based on a morphological assessment of modified Giemsa-stained smears of bone marrow (BM); immunophenotyping was performed by flow cytometry with a basic panel, which included cluster of differentiation 19 (CD19), CD20, CD22, CD4, CD3c, CD8, CD10, CD13, CD15, CD33, CD42b, CD117, myeloperoxidase (MPO), CD79a, CD34, terminal deoxynucleotidyl transferase (TdT), and human leukocyte antigen-antigen D related (HLA-DR). Cytogenetics, performed with multiplex reverse transcriptase-polymerase chain reaction analyses, was not mandatory.
Response and events definitions
Response was assessed in peripheral blood on day 8 and in BM on days 15 and 33. Patients who were not in complete remission (CR) by day 33 were evaluated after phase IB or after the subsequent high-risk (HR) blocks (see the Treatment, below). A prednisone poor response on day 8 was defined as having 1000 blasts/mm 3 in peripheral blood after 7 days of prednisone and 1 intrathecal dose of methotrexate (MTX). Bone marrow status was categorized as M1 (<5% blasts), M2 (5%-24% blasts), or M3 (25% blasts). CR was defined as M1 BM status with normal peripheral counts and no extramedullary disease. Resistant disease was defined as not experiencing CR after completing the 3 HR treatment blocks. Relapse was defined as the reappearance of at least 25% blasts in BM and/or extramedullary disease after experiencing CR. Treatment abandonment was defined as missing 4 or more consecutive weekly scheduled visits during therapy.
Risk-stratification criteria
Patients were classified into standard-risk (SR), intermediate-risk (IR), and HR groups according to the criteria summarized in Table 1 
Determination of nutritional status
Triceps skin-fold thickness (TSFT) and middle-upper arm circumference (MUAC) were measured to classify 
Treatment
The treatment is very similar to that in the ALL IC-BFM 2002 study 11 and is described in Table 2 . This treatment differs from the ALL IC-BFM 2002 protocol as follows: in phase IA, patients receive L-asparaginase at a dose of 10,000 U/m 2 intramuscularly (instead of 5000 U/m 2 intravenously); for HR block 2, vincristine is substituted for vindesine (not available); in protocol III, patients receive 6 mg/m 2 dexamethasone (rather than 10 mg/m 2 ), and 6-mercaptopurine is substituted for 6-thioguanine (not available); for maintenance, patients receive vincristine/ dexamethasone pulses given every 4 weeks (compared with no pulses). There are no randomized treatment arms. Since January 2013, patients with the breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL1) t(9;22) translocation have received imatinib at a dose of 300 mg/m 2 daily, which generally is started during induction phase IB and is continued until the end of treatment. Hematopoietic stem cell transplantation is not available in this treatment center.
Data Collection and Statistical Analysis
Demographic and clinical data were collected in the Pediatric Oncology Networked Database (www.POND4-Kids.org, Accessed September 09, 2016), a web-based database developed by the IOP at St. Jude Children's Research Hospital, and were analyzed in collaboration with the Statistical Office for Pediatric Hemato-Oncology in Low-Income Countries (University of Milano-Bicocca, Monza, Italy).
For the current analyses, overall survival (OS) was defined as the time from the beginning of treatment to death (from any cause) or the date of last follow-up (censored observation). Event-free survival (EFS) was defined as the time from the beginning of treatment until the first event from among induction failure (death or the appearance of resistant disease), relapse, death in CR, abandonment of treatment, occurrence of a second malignancy, or until the date of last follow-up if no event occurred. OS and EFS probabilities were estimated using the KaplanMeier method with Greenwood standard error (SE). The crude cumulative incidence (CI) of relapse and death also was estimated, accounting for competing events. EFS, OS, and CI also were estimated by stratifying patients according to risk group and clinically relevant characteristics: age (<10 years vs 10 years), white blood cell (WBC) count (<50,000/mm 3 vs 50,000/mm 3 ), National Cancer Institute (NCI) criteria (NCI SR patients aged <10 years with a WBC count <50,000/mm 3 at diagnosis vs NCI HR patients aged 10 years or a WBC count 50,000/mm 3 ), lineage (B vs T) and CNS status. A multivariate logistic regression analysis, which included WBC count, age, nutritional status, immunophenotype, and sex, was performed to identify the factors related to a higher risk of mortality in the induction phase. To identify which factors (sex, age, nutritional status, WBC count, prednisone response, and BM status on day 15) were mainly associated with the increased risk of an event, a multivariate Cox regression model with time-dependent covariates was run. Statistical comparisons were considered significant when the P value was < .05. Statistical analyses were carried out using SAS version 9.2 (SAS Institute Inc, Cary, NC) and R statistical software (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
From July 1, 2007, to June 30, 2014, 896 patients were diagnosed with ALL at UNOP. Of these, 109 patients (12.2%) were ineligible because of age (<1 year; n 5 17), previous antineoplastic treatment (n 5 64), or death before starting treatment (n 5 9). Treatment was refused for 19 patients by their parents (Fig. 1) . Thus, in total, 787 of 896 patients (87.8%) were enrolled in the LLAG-0707 study and were followed up to June 30, 2015, for a median of 3.6 years (interquartile range, 2.3-5.4 years). Molecular genetics were analyzed in 281 of the 787 patients (35.7%) using multiplex reverse transcriptase-polymerase chain reaction.
Demographic and Clinical Characteristics
The disease features at diagnosis are summarized in Table  3 . Treatment arm allocation was as defined according to the protocol in 98.1% of patients, and only 15 patients were shifted to a different arm as a result of a medical Original Article decision. Overall, 20.3% of patients were treated as SR, 57.2% were treated as IR, and 22.5% were treated as HR.
Treatment Results
The treatment results are outlined in Table 4 . Overall, 731 patients (92.9%) experienced CR. Of the 23 patients (2.9%) who were not in CR after phase IA, 14 experienced CR after phase IB, 6 died before experiencing CR, and 3 had resistant leukemia. When treatment abandonment was considered as an event, the 5-year EFS and OS ( 6 SE) rates were 56.2% 6 2.1% and 64.1% 6 2.0%, respectively (Fig. 2) ; and, when treatment abandonment was censored, the 5-year EFS and OS rates were 57.9% 6 2.1% and 65.7% 6 2.1%, respectively. By risk group, the 5-year EFS and survival rates ( 6 SE), with treatment abandonment considered as an event, were 71.1% 6 4.5% and 81.3% 6 4.1%, respectively, in the SR group; 58.2% 6 2.9% and 65.3% 6 2.8%, respectively, in the IR group; and 38.4% 6 4% and 46% 6 4.1%, respectively in the HR group (Fig. 3) .
Death During Induction
Overall, 52 patients died before experiencing CR (6.6%). These deaths resulted from infectious disease (n 5 32; 61.5%), hemorrhage (n 5 10; 19.2%), or other causes (n 5 10; 19.2%). Two patients died in the pretreatment phase, 44 died in phase IA, and 6 died in phase IB (of 23 patients who had no CR at the end of phase IA). Of the 46 patients who died in phase IA, 7 received no dose, 18 received 1 dose, and 20 received 2 doses of anthracyclines. One-third of the induction deaths that occurred in the period from January 2013 to June 2015 were caused by nosocomial, multidrug-resistant Acinetobacter baumanii infection. Logistic regression identified significant associations of hyperleukocytosis (WBC count 50,000/mm 3 ) and age (10 years) at diagnosis with a higher risk of death during induction (odds ratio, 2.95 [95% confidence interval, 1.63-5.36; P 5 .0004] and 2.05 [95% confidence interval, 1.14-3.7; P 5 .01], respectively); whereas the associations of nutritional status, immunophenotype, and sex were not significant. Methotrexate levels were measured, and the dose of leucovorin was adapted, according to a specific nomogram for higher levels of methotrexate. e The intensification protocol was received once by SR patients and twice by IR patients after consolidation therapy, and HR patients received it 3 times after HR blocks. f Maintenance was continued until the completion of treatment at week 104. g Cranial radiotherapy was indicated for patients aged 2 years; those with CNS 3 disease received therapeutic doses, whereas those with hypodiploidy, t(9;22) or t(4;11) translocations, T-lineage acute lymphocytic leukemia (T-ALL) with WBC counts > 50,000/mm 3 at diagnosis or a poor response to prednisone, and B-ALL with WBC counts >100,000/mm 3 at diagnosis who received prophylactic doses. 
Death in Continuous CR
Thirty-eight patients (4.8%) died in continuous CR (CCR), with 2-year CI rates ( 6 SE) of 3.9% 6 1.6%, 2.5% 6 0.7%, and 9.1% 6 2.2% for patients in the SR, IR, and HR groups, respectively. No patients in the SR or IR groups died during the consolidation phase (courses of high-dose methotrexate). The causes of death were infectious diseases in 31 of 38 patients (81.6%), hemorrhage in 3 patients, cardiotoxicity in 1 patient, an accident at home in 1 patient and unknown in 2 patients. No difference was observed in the CI of death in CCR by age (<10 vs 10 years). Deaths in CCR according to treatment phase included 12 deaths shortly after completing phase IA (because of complications with onset in this phase), 1 during phase IB, 6 during HR-block therapy, 7 during reinduction, 11 during maintenance, and 1 off therapy (an accident at home).
Relapses
Relapses occurred in 178 patients (22.6%), and most (118 of 178 relapses) occurred during therapy (median time to relapse: 1.64 years; interquartile range, 0.97-2.66 years) and were mainly isolated in BM (57.9%). The overall 2-year and 5-year CI rates of relapse ( 6 SE) were 13.4% 6 1.2% and 28.9% 6 2.0%, respectively; whereas, for patients in the SR, IR, and HR groups, the CI rates at 5 years after diagnosis were 19.4% 6 4.2%, 29.5% 6 2.7%, and 34.9% 6 3.9%, respectively.
Outcome by Clinical Features
The 5-year EFS rate ( 6 SE) by age (<10 years vs 10 years) was 60.1% 6 2.5% versus 47.2% 6 3.9%, respectively (P 5 .001); and the rate by WBC count (<50,000/ mm 3 vs 50,000/mm 3 ) was 63.4% 6 2.3% versus 32.7% 6 4.4%, respectively (P < .0001). In addition, the 5-year CIs of toxic death and relapse by age and WBC count were statistically different (Fig. 4A-D) . Patients ages 15 to 17 years (n 5 55) comprised 7% of the whole population and had a 5-year EFS rate of 34.9% 6 8.7%.
In a comparison of patients in the NCI SR and HR groups, the 5-year EFS rate was 68% 6 2.6% versus 40.3% 6 3.4%, respectively (P < .0001); and the differences in the 5-year CIs of death and relapse were significant (Fig. 4E,F) . Forty-six patients (5.8%) had T-lineage ALL, including 21 IR patients and 25 HR patients. The overall EFS rate in IR and HR patients at 5 years was 55% 6 7.9% versus 56.2% 6 2.2%, respectively, in patients with B-linage ALL (P 5 .6). The results obtained by applying a Cox regression model to each individual characteristic (univariate analysis) were compared with those obtained in the multivariate analysis (Table 5 ). The findings confirmed the independent prognostic value of the WBC count and a prednisone poor response on the hazard of events, whereas sex, age, nutritional status, and BM status on day 15 no longer had a significant impact. Ethnicity also was analyzed as a single characteristic, and there was no difference in the results (P 5 .9).
Outcome by Selected Chromosomal Abnormalities
Patients who had any unfavorable structural or numerical chromosomal abnormalities (t [9;22] , t [4;11] , or hypodiploidy) had a remission rate of 83% and relapse rate of 43%. The 3-year EFS and OS rates ( 6 SE) were 16% 6 10% and 31% 6 10%, respectively, when abandonment of treatment was considered as an event. Only 21 of the 281 patients tested had the ets variant 6/runt-related transcription factor 1 (ETV6/RUNX1) transcripts, and 14 remain in CCR. Of the 174 patients who were diagnosed with hyperdiploidy ALL (DNA index 1.16), 6 patients (3.4%) died during induction, and 11 (6.3%) died in CR as a result of toxicity; 168 patients (96.6%) experienced CR, 23 (13.2%) relapsed, and 126 (72.4%) remain in CCR (Table 6 ).
Down Syndrome
There were 8 patients with Down syndrome. Five of these patients remain in CCR with a median follow-up of 3.8 years after diagnosis.
Outcome in Patients not Eligible for the Study
An epidemiological evaluation of the entire cohort of 896 patients diagnosed at UNOP, with a median follow-up of 3.6 years, yielded a 5-year survival probability ( 6 SE) of 60.4% 6 1.9%. Of 109 patients who were not eligible for the protocol, 17 were infants (5 remain alive in CCR), and 64 were pretreated with chemotherapy (27 remain alive in CCR). Of the remaining patients (those who initially refused therapy or elected to receive palliative 
DISCUSSION
The presenting features at diagnosis in our study population differed from those reported in the ALL IC-BFM 2002 study 11 with respect to the incidence of T-lineage ALL (5.8% vs 12.7%, respectively), hyperleukocytosis (WBC count 100,000/mm 3 , 15% vs 10.2%, respectively), CNS 3 disease (12.5% vs 3.6%, respectively), and genetics. Distribution by age was similar in both cohorts, including the proportions of patients ages 15 to 17 years. These data corroborate findings from other studies of ALL in Central America, which report a higher percentage of patients with hyperleukocytosis than is reported in higher income countries, although there are fewer patients with of T-lineage ALL, and suggest that the diagnosis of ALL is delayed in LMICs, although this finding also may be related to the different genetic features of ALL in Guatemala. The high rate of patients with CNS 3 status remains intriguing. We will also prospectively assess this finding by flow cytometry to further clarify the issue.
Similar to other experiences in LMICs, 92 of 896 patients (10%, excluding infants) could not be recruited for the study because they had previously received treatment with antineoplastic agents (n 5 64, of whom 27 remain alive in CCR), refused treatment (n 5 19, of whom 2 remain alive), or died before starting treatment (n 5 9).
The incidence of treatment abandonment has been reduced from 23.4% in the 1990s 13 to 2.7% in the current study. This was obtained thanks to a strong intervention by the psychosocial service, which was able to classify the living conditions of patients at the time of diagnosis and to provide support, including a family food bag, Abbreviations: BM, bone marrow; CI, confidence interval; HR, hazard ratio; M1, < 5% BM blasts; M2, 5% to 24% BM blasts; M3, 25% BM blasts; WBC, white blood cell. The high incidence of induction deaths (6.6% overall, n 5 52; 1.9% in SR patients, 6.2% in IR patients, and 11.9% in HR patients) was mostly because of infectious complications (32 of 52 deaths). To assess whether anthracyclines played a role, we investigated the cumulative doses administered in patients who died during induction and observed that they had received a very limited amount. This was consistent with the protocol guidelines, which prescribed anthracyclines only to patients in good clinical condition. Thus, it appears that earlier diagnosis and better management of infectious complications may be more important than changes in chemotherapy during induction therapy.
The overall 5-year CI of death in CR for our cohort was similar to that for the ALL IC-BFM 2002 cohort (5% vs 5.3%, respectively). In our study, only 1 of 729 patients died in phase IB, indicating that this phase is quite safe. It is worth noting that deaths during the most intensive treatment phase (block therapy in HR patients) occurred with a frequency similar to that observed in Italian Pediatric Hematology and Oncology Association (AIEOP)-BFM studies, 14 suggesting that postinduction intensive therapy may also be feasible in LMICs in the context of a well developed pediatric oncology center.
Overall, 11.4% of patients died during induction or in CR. This also was observed in patients with hyperdiploidy, who still had suboptimal outcomes (72.4% patients in CCR), with one-third of events caused by toxic deaths.
Most deaths during induction or in CR were because of infectious complications, including Acinetobacter baumanii nosocomial infections. For this reason, specific strategies have been developed in collaboration with the infectious disease service of the St. Jude IOP and the Intensive Care Service at Boston Children's Hospital. In this project, a protocol for the management of febrile neutropenia 15 and the pediatric early warning score (PEWS) have been implemented. 16 In addition, a protocol for A. baumanii infections has been designed for treatment (based on meropenem, polymyxin B, and tygecycline) and infection control, with screening for A. baumanii colonization in patients referred from public hospitals and contact precautions for all colonized patients; also, hand hygiene, vascular access safety, isolation precautions, and environmental cleaning are reinforced. The impact of these measures will be further assessed in the next protocol. Malnutrition played no role in the outcome of this study; this finding confirms that an appropriate nutritional program may overcome the negative prognostic indication of malnutrition in treating childhood ALL, as previously reported. 12 The incidence of relapse is excessive compared with that in contemporary protocols conducted in higher income countries. 11 In part, this may be caused by the low rates of compliance and adherence to treatment, particularly with oral medications and during the continuation phase, which may be associated with a higher risk of relapse. 17, 18 Although we have no data to demonstrate the validity of this hypothesis, it can be suggested by the relatively high rates of relapse during treatment (2-year CI rate of relapse, 13.4% 6 1.2%) and by the relative frequency of very late relapses, as illustrated in Figure  4B ,D,F, compared with the AIEOP-BFM and ALL IC-BFM studies. 11, 19 The only factors that retained an independent statistically significant difference for the hazard of any event were WBC count and prednisone poor response.
To encourage adherence to treatment, a specific program has been organized by the pharmacists. Home medications are provided to the families in specific containers. When the subsequent order is provided, the previous container must be given back to the pharmacist, who can calculate whether the remaining drug is consistent with an appropriate administration. Furthermore, specific educational sessions are organized to explain to parents and adolescent patients the crucial importance of the correct intake of medications at home. This is also reinforced in by the psychosocial workers and pediatricians in the talks they have with parents and patients. The role of full treatment with anthracyclines, together with monitoring WBC counts as maintenance to reduce relapses, will be assessed in the next protocol. The pattern of relapses may be also influenced by the low incidence of the favorable translocation t(12;21) (which has an incidence of only 7.4% among the patients with B-precursor ALL investigated vs a 25% incidence usually reported) and high incidence of Philadelphia chromosome (Ph)-positive cases. However, further investigations are needed to substantiate these findings. Finally, the incidence of Ph-like childhood ALL in Guatemala may be high, as suggested by recent studies indicating a high frequency of the rs3824662 risk allele (associated with Ph-like ALL) in Guatemalans with high Native American genetic ancestry. [20] [21] [22] In the next
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protocol, all patients will be screened for ETV6/RUN-X1 t(12;21), BCR/ABL1 t(9;22), myeloid/lymphoid or mixed-lineage leukemia/acute lymphocytic leukemia-1 fused gene on chromosome 4 (MLL-AF4) t(4;11), transcription factor 3-pre-B-cell leukemia homeobox 1 (TCF3-PBX1) t(1;19), Nudix hydrolase family gene (NUDT), GATA binding protein 3 (GATA3), and ATrich interaction domain 5B (ARID5B).
The overall results from this study suggest that intensive therapy can be delivered in a well organized center in an LMIC and that treatment abandonment can be reduced to a very low incidence with promising results. However, these results remain suboptimal because of the socioeconomic conditions that are associated with a higher risk of late diagnosis and early death. Longer follow-up also is needed to determine whether a plateau at 5 years has been reached with this therapy. Further improvement in survival should be pursued through educational programs to facilitate earlier diagnosis, better management of infectious complications, better knowledge of the disease, and possibly different treatment strategies. 23, 24 In this context, efforts also should be made to identify patients who have thiopurine deficiency 5, 20 to prevent complications associated with severe, unexpected hematologic toxicity. An additional potential benefit may be derived from better treatment adaptation based on early minimal residual disease detection using methodologies that are applicable in centers with limited resources 25, 26 and may be successful in decreasing the treatment burden for patients who have the most favorable prognoses.
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